
Thermo Fisher Scientific Inc.
TMONYSEHealthcare● Active
$469.63
$-3.17(-0.67%)
Market Cap$174.5B
P/E Ratio—
52W High$643.99
52W Low$385.46
Thermo Fisher Scientific Inc.(TMO)· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · TMO · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $6.72B | $6.34B | $6.00B | $6.96B | $7.73B |
| Depreciation & Amort. | $2.78B | $3.11B | $3.41B | $3.38B | $2.59B |
| Stock-Based Comp. | $0.00B | $0.30B | $0.28B | $0.31B | $0.23B |
| Change in Working Capital | ($1.81B) | ($0.33B) | ($0.54B) | ($1.05B) | ($1.56B) |
| Net Cash from Operations | $7.82B | $8.67B | $8.41B | $9.15B | $9.54B |
| Investing Activities | |||||
| Capital Expenditure | ($1.52B) | ($1.40B) | ($1.48B) | ($2.24B) | ($2.52B) |
| Purchases of Investments | ($0.38B) | ($3.40B) | $0.00B | ($0.01B) | ($0.01B) |
| Sales of Investments | $1.56B | $1.77B | $0.07B | $0.01B | $0.01B |
| Net Cash from Investing | ($4.05B) | ($5.84B) | ($5.14B) | ($2.16B) | ($21.93B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($3.00B) | ($4.00B) | ($3.00B) | ($3.00B) | ($2.00B) |
| Dividends Paid | ($0.64B) | ($0.58B) | ($0.52B) | ($0.46B) | ($0.40B) |
| Debt Issued / Repaid | $5.35B | ($2.40B) | ($0.15B) | $0.65B | $8.91B |
| Net Cash from Financing | $1.80B | ($6.79B) | ($3.62B) | ($2.81B) | $6.58B |
| Free Cash Flow | |||||
| Free Cash Flow | $6.29B | $7.27B | $6.93B | $6.91B | $7.02B |
| FCF Margin %(computed) | 14.12% | 16.95% | 16.16% | 15.39% | 17.90% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-10 · USD · B
深入了解Thermo Fisher Scientific Inc.
关于Thermo Fisher Scientific Inc.(TMO)现金流量表
Thermo Fisher Scientific Inc. 2025财年经营活动现金流$7.82B,自由现金流$6.29B(FCF利润率14.12%),资本支出($1.52B)。
常见问题
TMO · 4 问Thermo Fisher Scientific Inc. 2025财年自由现金流$6.29B,同比down13.4%。
TMO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10